` GLAND (Gland Pharma Ltd) vs BSE Sensex 30 Comparison - Alpha Spread

GLAND
vs
BSE Sensex 30

Over the past 12 months, GLAND has underperformed BSE Sensex 30, delivering a return of -21% compared to the BSE Sensex 30's 1% growth.

Stocks Performance
GLAND vs BSE Sensex 30

Loading

Performance Gap
GLAND vs BSE Sensex 30

Sign Up to see
Performance Gap
Sign In
Sign Up

Performance By Year
GLAND vs BSE Sensex 30

Loading
GLAND
BSE Sensex 30
Add Stock

Competitors Performance
Gland Pharma Ltd vs Peers

BSE Sensex 30
GLAND
LLY
JNJ
NOVO B
ROG
Add Stock

Gland Pharma Ltd
Glance View

Economic Moat
None
Market Cap
243B INR
Industry
Pharmaceuticals

Gland Pharma Ltd., an Indian company with a robust heritage, has made its mark in the global pharmaceutical landscape primarily through its adeptness in injectable medication. Founded in 1978 by P.V.N. Raju, the company’s journey has been one of steady ascension, characterized by a firm commitment to quality and innovation. Operating in a market where precision and reliability are paramount, Gland Pharma has specialized in the development and manufacturing of complex generic injectables, a niche that demands rigorous regulatory compliance and state-of-the-art manufacturing capabilities. With its extensive product portfolio, Gland Pharma serves a diverse range of therapeutic areas, including anti-coagulants, anti-biotics, and anti-virus medications, catering to hospitals and healthcare facilities worldwide. This strategic focus has enabled the company to build a reputable name in both domestic and international markets, becoming a critical supplier in the intricate supply chain of modern healthcare. What distinguishes Gland Pharma from many contemporaries is its business model that hinges on backward integration and robust R&D capabilities. By taking charge of every aspect of production—from procuring raw materials to the final packaging—the company achieves cost efficiencies and ensures unwavering quality control. This integration extends beyond manufacturing, as Gland Pharma has cultivated strong relationships with strategic partners globally, facilitating its penetration into regulated markets such as the US, EU, and Australia. It harnesses these connections to distribute its products extensively while also acquiring ANDA (Abbreviated New Drug Application) approvals that cement its standing in these regions. Financially, Gland Pharma's revenue is largely derived from this steady export of generic injectables, riding on the ever-growing demand for affordable healthcare solutions. Through these strategic endeavors, the company encapsulates a blend of Indian manufacturing prowess and global pharmaceutical acumen, keeping its financial health robust and its market reach expansive.

GLAND Intrinsic Value
HIDDEN
Show
Back to Top